iiinova — where your digital self keeps evolving

rouchelles.bsky.social

@rouchelles.bsky.social

rouchelles.bsky.social @rouchelles.bsky.social · 23/01/2026

Thank you Irene Fernandez-Ruiz for this great piece of commentary in @natrevcardiol.nature.com on the IVORY trial published in @natmed.nature.com Main paper can be found here: rdcu.be/eX8W3 @ziadmallat.bsky.social @18fdg.bsky.social @vpd-hlri.bsky.social @medcambridge.bsky.social

074

Reposted by @rouchelles.bsky.social

VPD Heart & Lung Research Institute @vpd-hlri.bsky.social · 20/01/2026

Fresh off her @naturemedicine.bsky.social paper. @rouchelles.bsky.social talks balancing work and life, navigating academic cardiology as a woman, and why even top achievers face imposter syndrome. Read more ⬇️ rdcu.be/eX8W3 @nihr.bsky.social @royalpapworth.bsky.social

173

Reposted by @rouchelles.bsky.social

Charlotte Summers @charlottesummers.bsky.social · 20/01/2026

Please do have a listen to @rouchelles.bsky.social sharing her thoughts about her science, balancing a clinical academic career in cardiology with family life, & the importance of mentors and a supportive environment. @nihr.bsky.social @royalpapworth.bsky.social @cam.ac.uk

131

rouchelles.bsky.social @rouchelles.bsky.social · 19/01/2026

Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀 Main paper: rdcu.be/eX8W3 Commentary: rdcu.be/eYyG6 @jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social

044

Reposted by @rouchelles.bsky.social

Nature Medicine @natmed.nature.com · 17/01/2026

In a phase 2 trial, low-dose interleukin-2 boosted regulatory T cells and reduced arterial inflammation in acute coronary syndrome patients compared to placebo. www.nature.com/articles/s41591-025-…

066

Reposted by @rouchelles.bsky.social

James Rudd @18fdg.bsky.social · 15/01/2026

Amazing to be part of this team - please read the paper and let us know what you think! @rouchelles.bsky.social

011

Reposted by @rouchelles.bsky.social

jch403.bsky.social @jch403.bsky.social · 11/01/2026

A potential breakthrough in heart disease Cambridge medics tested a low-dose drug that ⬇️inflammation in blood vessels by ⬆️ protective immune cells. This mechanism won the 2025 Nobel Prize for Medicine Over 2 years Drug group: 0 events, placebo 11% www.nature.com/articles/s41... #HeartHealth

nature.com

Client Challenge

011

rouchelles.bsky.social @rouchelles.bsky.social · 12/01/2026

The IVORY trial was published in Nature Medicine last week. rdcu.be/eX8W3 This trial done in high-risk individuals who presented with heart attacks 🫀, showed low-dose interleukin-2 led to a ⬆️ Regulatory T cells ⬇️ Arterial inflammation 🔥 ⬇️ trend in adverse cardiovascular outcomes ❤️‍🔥 at 2 years

Commissioned artwork for the IVORY trial by Shaanea Mendis. Depicting regulatory T cells in blue which are calming down inflammation in blood vessels after heart attacks.

111

rouchelles.bsky.social @rouchelles.bsky.social · 12/01/2026

Thank you @vpd-hlri.bsky.social for the shout-out. Original article here: rdcu.be/eX8W3

rdcu.be

Client Challenge

021

rouchelles.bsky.social @rouchelles.bsky.social · 11/01/2026

Original article: rdcu.be/eX8W3

rdcu.be

Client Challenge

001

Reposted by @rouchelles.bsky.social

PARCC @parcc-inserm.bsky.social · 08/01/2026

Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation. Learn More: www.nature.com/articles/s41...

nature.com

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine

In a randomized phase 2 trial in patients with acute coronary syndrome and high levels of the inflammation biomarker C-reactive protein, treatment with low-dose interleukin-2 increased the numbers of ...

043

Reposted by @rouchelles.bsky.social

Daniel Drucker @danieljdrucker.bsky.social · 08/01/2026

After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation. www.nature.com/articles/s41...

nature.com

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial - Nature Medicine

152

rouchelles.bsky.social @rouchelles.bsky.social · 11/01/2026

Delighted to share that the results of the IVORY trial were published in Nature Medicine: rdcu.be/eX8W3 This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.

rdcu.be

Client Challenge

020